Silence Therapeutics Plc (SLN) ADR EACH REPR 3 ORD SHS SPON

Sell:$4.65Buy:$5.50$0.21 (4.20%)

Prices delayed by at least 15 minutes
Sell:$4.65
Buy:$5.50
Change:$0.21 (4.20%)
Deal now
Prices delayed by at least 15 minutes
Sell:$4.65
Buy:$5.50
Change:$0.21 (4.20%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.

Key people

Craig A. Tooman
President, Chief Executive Officer, Executive Director
J.P Gabriel
Chief Technical Operations Officer
Marie Wikstrom Lindholm
Chief Scientific Officer
Curtis Rambarn
Chief Medical Officer
Steven J. Romano
Head of Research and Development
Rhonda Heliums
Secretary
Iain Gladstone Ross
Non-Executive Chairman of the Board
Michael Harvey Davidson
Non-Executive Independent Director
James Lawrence Ede-Golightly
Non-Executive Independent Director
David Jakob Lemus
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US82686Q1013
  • Market cap
    $232.82m
  • Employees
    115
  • Shares in issue
    141.64m
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.